Trastuzumab emtansine versus trastuzumab plus pertuzumab for HER2-positive breast cancer with residual disease after neoadjuvant therapy: a real-world study - Poll - MDSpire

Trastuzumab emtansine versus trastuzumab plus pertuzumab for HER2-positive breast cancer with residual disease after neoadjuvant therapy: a real-world study

  • By

  • Zhong Wang

  • Yimin Zhang

  • Feng Yao

  • Jinxin Li

  • Chenyuan Li

  • Shichong Liao

  • June 18, 2026

  • 0 min

Share

Original Source(s)

Trastuzumab emtansine versus trastuzumab plus pertuzumab for HER2-positive breast cancer with residual disease after neoadjuvant therapy: a real-world study

  • by Zhong Wang, Yimin Zhang, Feng Yao, Jinxin Li, Chenyuan Li, Shichong Liao

  • June 18, 2026

Related Content

Case Report: Exchange transfusion for hemolytic anemia and acute kidney injury associated with hepatic arterial infusion chemotherapy with raltitrexed and oxaliplatin in a patient with hepatocellular carcinoma

A Case Report of follicular dendritic cell sarcoma

Polygenic Risk Scores for Breast Cancer Among African American Women With High Risk